Demonstrating that Real World Evidence Is Fit-For-Purpose to Support Labeling: Parallels to Patient Reported Outcomes in the Pursuit of Labeling Claims
| Autor: | Karolina Andersson Sundell, Robert J Meyer, Cynthia J. Girman, Ann Marie McNeill, Mary E. Ritchey |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Product Labeling
Actuarial science Public Health Environmental and Occupational Health Context (language use) 030226 pharmacology & pharmacy 01 natural sciences Clinical trial 010104 statistics & probability 03 medical and health sciences 0302 clinical medicine Paradigm shift Data quality Content validity Pharmacology (medical) Observational study 0101 mathematics Psychology Pharmacology Toxicology and Pharmaceutics (miscellaneous) Parallels |
| Zdroj: | Therapeutic Innovation & Regulatory Science. 55:561-567 |
| ISSN: | 2168-4804 2168-4790 |
| Popis: | In December 2021, U.S. Food & Drug Administration (FDA) will issue guidance on the use of real-world evidence (RWE) to support new indications or expanded product labeling. While difficult to foresee what FDA will require, learnings can be gleaned from previous paradigm shifts at FDA, such as for patient reported outcomes (PROs) in 2006–2009. We contrast published requirements for justifying PROs as fit-for-purpose for a specific labeling claim with a potential approach to justify RWE as fit-for-purpose to support expanded labeling or a new indication. PRO labeling claims require a PRO Evidence Dossier that includes: specific wording of claim, clinical trial hypothesis structure and endpoint model, and justification that the PRO is relevant and meaningful to patients in the target population (content validity) with adequate psychometric properties. FDA’s 2018 RWE Framework outlined critical considerations for using RWE to support regulatory decisions, including data quality, relevancy, provenance, and transparency. Strong parallels exist between the evidence required to justify that PROs are fit-for-purpose to support specific labeling claims and evidence to justify RWE as fit-for-purpose for specific research questions and labeling. Early discussion with FDA is encouraged. Drawing on parallels with use of PROs in labeling, RWE for regulatory purposes should be evaluated within the context of specific labeling or indication, specific study design and analysis plans, and the data attributes of data source. Sponsors seeking a new indication or labeling expansion based on RWE should justify that a specific data source and specific study design are fit-for-purpose. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink